Imcyse SA

📍 LIEGE, Belgium🗓 Founded 2011👥 57 employees💰 Last funded 2020
Biotechnology Research🌐 imcyse.com
Website LinkedIn
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2011
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Germany
1
Belgium
1
Frequently asked questions
Who invested in Imcyse SA?
Imcyse SA has 2 investors on record on gritt.io and 2 late-stage investors.
When did Imcyse SA last raise funding?
The most recent investment in Imcyse SA recorded on gritt.io was in 2020.
When was Imcyse SA founded?
Imcyse SA was founded in 2011.
What industry is Imcyse SA in?
Imcyse SA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Imcyse SA based?
Imcyse SA is headquartered in LIEGE, Belgium.